Immuno-PET in Pontine Glioma: More Than Meets the Eye?

WJG Oyen, C Jones - Journal of Nuclear Medicine, 2018 - Soc Nuclear Med
Overexpression of a membrane-associated target on tumor or immune cells, or of a factor in
the tumor microenvironment, is a major determinant of whether a patient can be treated with …

Molecular drug imaging: 89Zr-bevacizumab PET in children with diffuse intrinsic pontine glioma

MH Jansen, SEMV van Zanten… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Predictive tools for guiding therapy in children with brain tumors are urgently needed. In this
first molecular drug imaging study in children, we investigated whether bevacizumab can …

Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma

SEMV van Zanten, ACP Sewing… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Inadequate tumor uptake of the vascular endothelial growth factor antibody bevacizumab
could explain lack of effect in diffuse intrinsic pontine glioma. Methods: By combining data …

Immuno-PET for tumor targeting

FT Lee, AM Scott - Journal of Nuclear Medicine, 2003 - Soc Nuclear Med
Monoclonal antibodies are approved for use as diagnostics and therapeutics in a broad
range of medical indications including transplantation, cardiology, inflammatory diseases …

Bone and Lymph Node Metastases From Neuroblastoma Detected by 18F-DOPA-PET/CT and Confirmed by Posttherapy 131I-MIBG but Negative on Diagnostic 123I …

U Demirsoy, H Demir, F Corapcoglu - Clinical Nuclear Medicine, 2014 - journals.lww.com
We read the “Interesting Image” report of Piccardo et al 1 with deep interest. We, as pediatric
oncologists, generally are not well informed about technical details of interesting image …

18F-FLT-PET uptake dynamics and overall survival predictions for patients with recurrent high-grade glioma on bevacizumab therapy

J Schwarzenberg, J Czernin, T Cloughesy, C Geist… - 2011 - Soc Nuclear Med
274 Objectives The grim prognosis of patients with malignant glioma has recently been
somewhat brightened by antiangiogenic treatment with bevacizumab. Although not effective …

Comparison of PET imaging with 89Zr-Bevacizumab and 18F-FDG in a murine model of a human glioma cell line

S Rice, B Zeglis, J Lewis - 2011 - Soc Nuclear Med
138 Objectives The process of neovascularization via angiogenesis is necessary for the
growth and spread of cancer; Vascular endothelial growth factor (VEGF) plays an integral …

Bullets to magic bullets--and miles to go before we sleep

A Lovqvist, C Divgi - The Journal of Nuclear Medicine, 1998 - search.proquest.com
In this issue of the Journal of Nuclear Medicine, Klivenyi et al.(1) highlight the advantages
and limitations in their studies of pretargeting xenografted tumor using a bispecific …

[HTML][HTML] Immuno-PET for Glioma Imaging: An Update

MS De Feo, GM Granese, M Conte, B Palumbo… - Applied Sciences, 2024 - mdpi.com
Despite significant advances in glioma diagnosis and treatment, overall outcomes remain
suboptimal. Exploring novel therapeutic avenues show promise in advancing the field …

Brain Metastasis from Neuroblastoma Depicted by 18F-DOPA PET/CT

A Piccardo, G Morana, M Massollo, M Pescetto… - Nuclear medicine and …, 2015 - Springer
A 12-year-old boy with stage 4 neuroblastoma (NB), treated according to the SIOPEN-HR-
NB-01 protocol [1], presented with recent onset of headache and vomiting at the end of the …